A Phase 1 interventional study of Salmeterol/fluticasone Easyhaler and Salmeterol/fluticasone Easyhaler with charcoal in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.
Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2016, is one of 12 in phase 1, and was the 16th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2009; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 72 across the 19 interventional studies, 130 across the 2 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus 50/500 µg/inhalation; a randomised, open, single centre, single dose, crossover study in healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose of Salmeterol/fluticasone Easyhaler
Drug: Salmeterol/fluticasone Easyhaler
Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
Drug: Salmeterol/fluticasone Easyhaler with charcoal
Single dose of Seretide Diskus
Drug: Seretide Diskus
Single dose of Seretide Diskus with concomitant charcoal administration
Drug: Seretide Diskus with charcoal
Drug pages: FluticasoneStudies of FluticasoneFluticasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Salmeterol XinafoateStudies of Salmeterol XinafoateSalmeterol Xinafoate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Cmax of plasma salmeterol and fluticasone propionate
Time frame: 0 hour to 34 hours after study treatment administration
AUCt of plasma salmeterol and fluticasone propionate
Time frame: 0 hour to 34 hours after study treatment administration
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2016 to primary completion in Nov 2016, 4 months.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 4 months is below that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma →